The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money.

On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the stock.

everything possible/Shutterstock.com

H.C. Wainwright noted that Retatrutide’s clean low-dose profile alongside Pfizer’s once-monthly injectable establishes a new benchmark within the identical mid-body mass index market that oral treatments are targeting. Consequently, the firm cited increasing competitive pressure as the primary reason for the price target reduction.

On June 6, Structure Therapeutics Inc. (NASDAQ:GPCR) announced Phase 2b ACCESS trial results for aleniglipron in Nature Medicine. A lower 2.5 mg starting dose improved tolerability. Furthermore, weight loss persisted beyond 36 weeks, shaping the Phase 3 trials scheduled for the third quarter of 2026.

Patients actually kept shedding weight during the extension phase without hitting a plateau. According to Steering Committee Chair Dr. Julio Rosenstock, MD, this continuous weight loss makes the daily oral drug a highly unique option for patients.

Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs. The company is currently working on several drug candidates, which include GSBR-1290, ACCG-2671, ACCG-3535, LTSE-2578, and ANPA-0073. Additionally, it also develops programs like the GCG and GIPR programs.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.